Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

05 February 2022: Review Articles

A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract

Xuqiang Liao 1AE* , Gao Li 1B* , Renzhong Cai 1AF* , Ru Chen 2AG*

DOI: 10.12659/MSM.935348

Med Sci Monit 2022; 28:e935348

Table 2 Controversial findings of the predictive value of PD-L1 expression for the efficacy of immunotherapy in gastrointestinal tumors.

BiomarkerTumorStudyDrugCorrelation
PD-L1 expression in tumor cellsHCCCheckMate-040 []22 NivolumabNo significant correlation
PD-L1 expression in tumor cellsGCAttraction-2 []15 NivolumabNo significant correlation
PD-L1 expression in tumor cells, lymphocytes, and macrophagesGC/GEJCKEYNOTE-059 []16 PembrolizumabSignificantly relevant
PD-L1 expression in tumor cells, lymphocytes, and macrophagesHCCKEYNOTE-224 []29 PembrolizumabSignificantly relevant
PD-L1 expression in tumor cells, lymphocytes, and macrophagesECKEYNOTE-180 []30 PembrolizumabNo significant correlation
HCC – hepatocellular carcinoma; GC or GEJC – gastric or gastroesophageal junction cancer; EC – esophageal cancer; PD-L1 – programmed death-1 ligand-1.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750